News
Kailera, Hengrui stake claim to oral weight loss category
Chasing Novo Nordisk and Eli Lilly, Kailera and Hengrui have reported 12.1% weight loss in phase 2 with their oral GIP/GLP-1 agonist ribupatide.
News
Takeda signs $1.7bn AI alliance with Iambic
Iambic bags another pharma partner, Takeda, which plans to use its AI platform to find drugs for cancer, gastrointestinal, and inflammatory disorders.
R&D
AMR and vaccines: Can universal coverage avert a post-antibi...
Antimicrobial resistance (AMR) is a growing global health crisis.
R&D
Treating the chronic diseases GLP-1s miss, with Laurent Auda...
Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.
News
Lilly strikes again, buying CAR-T firm Orna for $2.4bn
In its second major deal in two days, Eli Lilly has reached an agreement to buy in vivo CAR-T developer Orna Therapeutics for up to $2.4bn.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
